Diagnostic value of glycophorin-A in comparison with P57 immunohistochemical staining method in differentiating complete and partial molar pregnancies.


Journal

Annals of diagnostic pathology
ISSN: 1532-8198
Titre abrégé: Ann Diagn Pathol
Pays: United States
ID NLM: 9800503

Informations de publication

Date de publication:
Aug 2021
Historique:
received: 22 04 2021
revised: 16 05 2021
accepted: 06 06 2021
pubmed: 20 6 2021
medline: 15 12 2021
entrez: 19 6 2021
Statut: ppublish

Résumé

Current histomorphological criteria in distinguishing two subtypes of hydatidiform moles has considerable inter-observer variability and limitations. In this regard, ancillary studies can aid pathologist to obtain an accurate diagnosis. Herein, we evaluated the utility of Glycophorin-A (GLA) in differentiating complete and partial moles. In this case-control study, formalin-fixed paraffin-embedded blocks of 47 patients with pathologic diagnosis of complete and 42 partial hydatidiform moles were included and the diagnoses were confirmed by immunohistochemistry (IHC) for P57. Sections from all samples were stained for GLA using IHC method. Using 2 × 2 tables, the sensitivity, specifity, Positive and Negative Predictive Values (PPV and NPV) as well as accuracy of GLA were determined. Primary pathologic diagnosis was changed in 7.1% and types of hydatidiform mole were specified in 11.9% of the cases after review of the slides and IHC study for P57. NRBCs were found in 52.7% of the PM cases and none of CMs by pathologist in H&E sections. IHC study for GLA revealed positive result in one case of complete moles (2%) and 31 case of partial mole samples (73.8%). It was negative in 98% of the complete mole and 11 (26.2%) of partial mole cases. The results of this study showed a significant association between GLA immunoreactivity and type of molar pregnancy. Diagnostic sensitivity, specificity and accuracy of this marker for discrimination of molar pregnancy were 73.8%, 98% and 86.5%, respectively. Therefore, this marker can be utilized in differentiating partial and complete hydatidiform mole.

Identifiants

pubmed: 34146830
pii: S1092-9134(21)00069-1
doi: 10.1016/j.anndiagpath.2021.151769
pii:
doi:

Substances chimiques

CDKN1C protein, human 0
Chorionic Gonadotropin, beta Subunit, Human 0
Cyclin-Dependent Kinase Inhibitor p57 0
Glycophorins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

151769

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Auteurs

Fatemeh Nili (F)

Department of pathology, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.

Sara Babazadeh (S)

Department of pathology, Ayatollah Rouhani Hospital, Babol University of Medical Sciences, Babol, Iran. Electronic address: babazadeh.sara@gmail.com.

Soheila Sarmadi (S)

Department of pathology, Yas Women Hospital, Tehran University of Medical Sciences, Tehran, Iran.

Fereshteh Ameli (F)

Department of pathology, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.

Hana Saffar (H)

Department of pathology, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH